Unique Quality by Design Approach for Developing HPLC and LC-MS Method for Estimation of Process and Degradation Impurities in Pibrentasvir, Antiviral Agent for Hepatitis C
Open Access
- 15 December 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (51) , 47650-47661
Abstract
Pibrentasvir (PIB) was approved for treating hepatitis C patients. A specific, accurate, linear, robust, and stability-indicating method was developed and validated for determining degradation impurities present in the PIB drug substance by studying the quality by design (QbD) principles. All identified degradation impurities were separated with the stationary phase HALO C18, 150 mm × 4.6 mm, 2.7 μm. Mobile phase A contains pH 2.5 phosphate buffer and acetonitrile in the ratio of (70:30, v/v), and mobile phase B contains water and acetonitrile in the ratio of (30:70, v/v), respectively. The chromatographic conditions were optimized, such as flow rate of 0.8 mL/min, UV detection at 252 nm, injection volume of 20 μL, and column temperature of 40 °C. The proposed method was validated per the current ICH Q2 (R1) guidelines. The recovery study and linearity ranges were established from limit of quantification (LOQ) to 300% optimal concentrations. The method validation results were between 98.6% and 106.2% for recovery, and linearity r 2 was more than 0.999 for all identified impurities. The method precision results achieved below 5% relative standard deviation (RSD). The forced degradation results demonstrated that the drug was sensitive to chemical stress conditions. During the stress study, degrading impurities were identified by the LC-MS technique and the mechanism pathway. A QbD-based experimental design (DoE) approach was used to establish the robustness of the method.Keywords
This publication has 10 references indexed in Scilit:
- Green Liquid Chromatography Method for the Determination of Related Substances Present in Olopatadine HCl Nasal Spray Formulation, Robustness by Design ExpertJournal of AOAC INTERNATIONAL, 2022
- Development and validation of liquid chromatography method for determination of Ibrutinib in finished dosage forms using quality by design approachSeparation Science Plus, 2022
- Unique green chromatography method for the determination of serotonin receptor antagonist (Ondansetron hydrochloride) related substances in a liquid formulation, robustness by quality by design‐based design of experiments approachJournal of Separation Science, 2022
- A Quality by Design and green LC technique for the determination of mast cell stabilizer and histamine receptor antagonist (Olopatadine HCl) in multiple formulationsBiomedical Chromatography, 2022
- Stability-indicating HPLC method for simultaneous estimation of Glecaprevir and Pibrentasvir, application to in-vitro dissolution studiesResearch Journal of Pharmacy and Technology, 2021
- Development and Validation of a Stability-indicating Method for Ibrutinib: Identification and Separation of Degradation Products, Known and Genotoxic Impurities Using RP-HPLC/PDA and QDa Mass DetectorsAnalytical Chemistry Letters, 2020
- Stability indicating RP-HPLC method development and validation for the simultaneous estimation of pibrentasvir and glecaprevir in bulk and pharmaceutical dosage formInternational Journal of Research in Pharmaceutical Sciences, 2019
- Development of validated stability indicating RP-HPLC method for the estimation of glecaprevir and pibrentasvir in bulk and pharmaceutical dosage formJournal of Applied Pharmaceutical Science, 2019
- A New Stability-Indicating RP-HPLC-Pda Method for Simultaneous Estimation of Glecaprevir and Pibrentasvir in tablet dosage formResearch Journal of Pharmacy and Technology, 2019
- A New Force Indicating RP-HPLC Method Development and Validation for the Simultaneous Estimation of Pibrentasvir and Glecaprevir in Bulk and its Tablet Dosage FormPharmaceutical Methods, 2018